<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="478">
  <stage>Registered</stage>
  <submitdate>9/09/2005</submitdate>
  <approvaldate>9/09/2005</approvaldate>
  <actrnumber>ACTRN12605000361606</actrnumber>
  <trial_identification>
    <studytitle>Adjuvant Chemotherapies in Resectable Pancreatic Cancer</studytitle>
    <scientifictitle>Adjuvant Chemotherapies in Resectable Pancreatic Cancer</scientifictitle>
    <utrn />
    <trialacronym>ESPAC-3</trialacronym>
    <secondaryid>ESPAC-3</secondaryid>
    <secondaryid>National Clinical Trials Registry: NCTR405</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Histologically proven ductal or ampullary cancer of the pancreas having undergone 'curative' resection</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Pancreatic</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Gemcitabine vs 5-FU/leucovorin</interventions>
    <comparator>Observation</comparator>
    <control>Historical</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>2 year survival</outcome>
      <timepoint>At 2 years.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Toxicity</outcome>
      <timepoint>Baseline, weekly during treatment then 3 monthly for 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life</outcome>
      <timepoint>Baseline, 3, 6, 9, 12 months and annually thereafter for 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>5-year survival</outcome>
      <timepoint>5 years post study entry</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>*  Patients who have undergone complete macroscopic resection for ductal adenocarcinoma of the pancreas (R0 or R1 resection) or patients with other cancers may be included who have had complete macroscopic resection (R0 or R1 resection) for (i) unusual malignancies of the pancreas, such as acinar cell carcinoma, cystadenocarcinoma etc.; (ii) cancers of the periampullary region; (iii) cancers of the intra-pancreatic part of the bile duct; (iv) periampullary cancers of uncertain origin.  Patients with tumours as in 1(b) will be analysed separately and will be in addition to the recruitment of pancreatic cancer patients.*  Histological confirmation of the primary diagnosis.*  Histological examination of all resection margins.*  No evidence of malignant ascites, liver metastasis, spread to other distant abdominal organs, peritoneal metastasis, spread to extra-abdominal organs.*  WHO performance status &lt; 2*  Fully recovered from the operation and fit to take part in the trial.  Life-expectancy of more than 3 months.*  Able to attend for administration of the adjuvant therapy.*  Able to attend for long-term follow-up.*  No previous or concurrent malignancy diagnoses (except curatively-treated basal cell carcinoma of skin, carcinoma in situ of cervix).*  No serious medical or psychological condition precluding adjuvant treatment.*  Fully informed written consent given.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>* Use of neo-adjuvant chemotherapy or other concomitant chemotherapy.
* Patients with pancreatic lymphoma.
* Macroscopically remaining tumour (R2 resection)
* Patients with TNM Stage IVb disease.
* Patients younger than 18 years.
* Pregnancy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Open Randomisation</concealment>
    <sequence>Computer software with blocking as stratification</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Factorial</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/10/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1090</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,ACT,QLD,SA,WA,TAS</recruitmentstate>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>North Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>South Island</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Australasian Gastro-Intestinal Trials Group (AGITG)</primarysponsorname>
    <primarysponsoraddress>Level 6, Medical Foundation Building The University of Sydney 92-94 Parramatta Road, Camperdown NSW 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC Project Grant</fundingname>
      <fundingaddress>N/A</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Cancer Council Australia</fundingname>
      <fundingaddress>N/A</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Over 1,650 Australians are diagnosed with pancreatic cancer each year. In most cases, surgery will remove the tumour but it is possible that the cancer will return as a result of undetectable disease (micrometastases).  The cancer will return and be incurable in the majority of patients, more than 1600 Australians die of the disease every year. 
  
This study compares the impact of adding chemotherapy to the surgery alone (the current standard of care). The study will also compare the effectiveness of two different types of chemotherapy.  

Surgical resection of a pancreas tumour is the current standard of care for this disease. It is possible that people treated with chemotherapy after their tumour has been surgically removed may live longer before their disease returns and may liver longer overall. This has been shown to be true in other in cancers; eg. breast and bowel. The side effects of chemotherapy are important and can be severe in some people. Recent studies in advanced pancreatic cancer have suggested that the new drug gemcitabine may be more effective than other drugs.  For this reason, the trial compares the outcomes in people treated with gemcitabine to those treated with an older drug 5FU, which has been shown to improve survival in an earlier study by the European group. 

This trial will determine if chemotherapy in addition to surgery increases disease-free and overall survival.  If it does, it should become standard practice. This study is an important international initiative that will provide unique information about effectiveness of these treatments and their impact on quality of life from the patient's perspective. This study and the previous European study are the largest of their type ever done. 900 people will take part. This study is being conducted in Australia by the Australasian Gastro-Intestinal Trials in collaboration with the Australian Hepatobilary Association and the NHMRC Clinical Trials Centre.</summary>
    <trialwebsite>http://www.gicancer.org.au/; http://www.ctc.usyd.edu.au/</trialwebsite>
    <publication>Conference Paper: Continuation of an adjuvant therapy trial in the light of new evidence: Revised design of the European Study Group for Pancreatic Cancer 3 trial (ESPAC-3) (2003). Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting			
Authors: Padbury, R;Goldstein, D;Knight, E;Dhillon, H;Tebbutt, N;Yip, S;Simes, J

Journal Article: Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. (2009), 100(2): 246-250	, BRIT J CANCER.
Authors: Neoptolemos, J P;Stocken, DD;Tudur Smith, C;Bassi, C;Ghaneh, P;Owen, E;Moore, M;Padbury, R;Doi, R;Smith, D;Buchler, MW

Conference Paper: ESPAC-3(v2): a multicentre, international, open label, randomised controlled phase III trial of adjuvant 5-fluorouracil/folinic acid versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma. (2009), 27(18S): Abs#LBA4505, American Society of Clinical Oncology Annual Meeting, J CLIN ONCOL.
Authors: Neoptolemos, J;BÃ¼chler, M;Stocken, DD;Ghaneh, P;Smith, D;Bassi, C;Moore, M;Cunningham, D;Dervenis, C;Goldstein, D

Journal Article: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. (2010), 304(10): 10731081, JAMA.
Authors: Neoptolemos, JP;Stocken, DD;Bassi, C;Ghaneh, P;Cunningham, D;Goldstein, D;Padbury, R;Moore, MJ;Gallinger, S;Mariette, C;Wente, MN;Izbicki, JR;Friess, H;Lerch, MM;Dervenis, C;Olah, A;Butturini, G;Doi, R;Lind, PA;Smith, D;Valle, JW;Palmer, DH;Buckels, JA;Thompson, J;McKay, CJ;Rawcliffe, CL;Buchler, MW;Cancer, for the European Study Group for Pancreatic Cancer.

Conference Paper: Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of Vater.(2011), 29(S): Abs#LBA4006, American Society of Clinical Oncology Annual Meeting, J CLIN ONCOL.
Authors: Neoptolemos, JP;Moore, MJ;Cox, TF;Valle, JW;Palmer, DH;McDonald, A;Carter, R;Tebbutt, NC;Dervenis, C;Smith, D;Glimelius, B;Coxon, FY;Lacaine, F;Middleton, R;Ghaneh, P;Bassi, C;Halloran, C;Olah, A;Rawcliffe, CL;BÃ¼chler, MW;Cancer, European Study Group for Pancreatic Cancer.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Hospital</ethicname>
      <ethicaddress>Commercial Road, Melbourne VIC 3004</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Adelaide Cancer Centre</ethicname>
      <ethicaddress>Suite 10, Level 1, Tennyson Centre
520 South Road, Kurralta Park SA 5037</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Repatriation Medical Centre</ethicname>
      <ethicaddress>145 Studley Road, Heidelberg VIC 3084</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bankstown-Lidcombe Hospital</ethicname>
      <ethicaddress>70 Eldridge Road, Bankstown NSW 2200</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Border Medical Oncology</ethicname>
      <ethicaddress>Suite 1/69 Nordsvan Drive, Wodonga VIC 3690</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Campbelltown Hospital</ethicname>
      <ethicaddress>Therry Rd, Campbelltown NSW 2560</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Canberra Hospital</ethicname>
      <ethicaddress>The Canberra Hospital /Yamba Drive, Garran ACT 2605</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch Hospital</ethicname>
      <ethicaddress>Riccarton Avenue, Christchurch 8011</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Flinders Medical Centre</ethicname>
      <ethicaddress>Flinders Drive, Bedford Park SA 5042</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Frankston Hospital</ethicname>
      <ethicaddress>Hastings Road, Frankston VIC 3199</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Launceston General Hospital</ethicname>
      <ethicaddress>274-280 Charles Street, Launceston TAS 7250</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Lismore Hospital</ethicname>
      <ethicaddress>60 Uralba Street  Lismore NSW 2480</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Hospital</ethicname>
      <ethicaddress>Elizabeth St, Liverpool NSW 2170</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash Medical Centre</ethicname>
      <ethicaddress>246 Clayton Road, Clayton VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Nepean Hospital</ethicname>
      <ethicaddress>Derby St, Kingswood NSW 2747</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Mater Misericordiae Hospital</ethicname>
      <ethicaddress>Edith Street, Waratah NSW 2300</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress>Barker Street, Randwick NSW 2031</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Queen Elizabeth Hospital</ethicname>
      <ethicaddress>28 Woodville Road, Woodville South SA 5011</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress>North Terrace, Adelaide SA 5000</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Hobart Hospital</ethicname>
      <ethicaddress>48 Liverpool Street, Hobart TAS 7000</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal North Shore Hospital</ethicname>
      <ethicaddress>Reserve Road, St Leonards NSW 2065</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress>Sydney Cancer Centre, Missenden Road, Camperdown NSW 2050</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress>Hospital Avenue, Nedlands, Perth 6009</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sydney Haematology and Oncology Clinics</ethicname>
      <ethicaddress>13/49 Palmerston Road, Hornsby NSW 2077</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent's Hospital, Melbourne</ethicname>
      <ethicaddress>41 Victoria Parade, Fitzroy VIC 3065</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St. Andrews Hospital</ethicname>
      <ethicaddress>280 North Street, Toowoomba QLD 4350</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Tweed Hospital</ethicname>
      <ethicaddress>Corner Powell Street &amp; Florence Street, Tweed Heads NSW 2485</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Wellington Hospital</ethicname>
      <ethicaddress>Riddiford Street, Newtown Wellington 6021</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Wesley Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Western Hospital</ethicname>
      <ethicaddress>148 Gordon Street, Footscray VIC 3011</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress>Corner of Hawkesbury Road and Darcy Road, Westmead NSW 2145</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>University of Sydney Human Research Ethics Committee (HREC)</ethicname>
      <ethicaddress>USYD HREC - Office of Research Integrity
Level 6, Jane Foss Russell Building G02
University of Sydney NSW 2006</ethicaddress>
      <ethicapprovaldate>19/02/2002</ethicapprovaldate>
      <hrec>02-2002/2661</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>ESPAC-3 Trial Coordinator</name>
      <address>National Health and Medical Research Council (NHMRC) Clinical Trials Centre Locked Bag 77 Camperdown NSW 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax>+61 2 9562 5094</fax>
      <email>ESPAC3@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>ESPAC-3 Trial Coordinator</name>
      <address>National Health and Medical Research Council (NHMRC) Clinical Trials Centre
Locked Bag 77
Camperdown NSW 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax>+61 2 9562 5094</fax>
      <email>espac3@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>ESPAC-3 Trial Coordinator</name>
      <address>National Health and Medical Research Council (NHMRC) Clinical Trials Centre Locked Bag 77 Camperdown NSW 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax>+61 2 9562 5094</fax>
      <email>espac3@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>